Standard Motion · S4M-15746 · Session 4
Widening Patient Access to Specialist Medication
The motion
That the Parliament understands that some of the most vulnerable people in Scotland face high prices to access new medications that have been denied or restricted by the Scottish Medicines Consortium (SMC); believes that the SMC has not recommended NHS use of the anti-breast cancer drug, Kadcyla, on the grounds of cost effectiveness, despite agreeing that it helps successfully to prolong the lives of younger women who are being treated for aggressive forms of the disease; understands also that, because of the price of the medication, prioritisation for treatment with all of the new medicines for hepatitis C is given to people with already highly-damaged livers; believes that, as it can be considered to be in the national interest, the Patents Act 1977 gives the Scottish Government the ability to invoke Crown-use provisions to disregard the patent on such drugs and either manufacture them itself or import much cheaper generic alternatives, and considers that such an approach should be assessed by ministers as a strategy to make vital medication available for all who need them.
Signatures by party
6 MSPs besides the lodger · 6 from other partiesLab 2Ind 2Green 2
Party on the day each MSP signed. Signing a motion is voluntary and not whipped. Who signs whose motions
Vote
No recorded vote on this motion. Most motions are never debated, and many that are debated are agreed without a division. Vote records are published from 2011.
Supporters
6 MSPsLab 2 Ind 2 Green 2
Show all 6 supporters by party
Lab 2
Ind 2
Green 2
Party shown is each supporter’s party when the motion was published.
In the Official Report
No contribution in the Official Report cites S4M-15746 by reference.